The data available to US Preventive Services Task Force didn't address an important question: what do you recommend to African American men who are twice as likely to develop prostate cancer and die from it as the general population?
Bristol-Myers Squibb's three-year collaboration with Flatiron Health will focus on leveraging real-world data to improve the pharmaceutical company's regulatory submissions, demonstrate the economic value of BMS's cancer portfolio, and to study the predictive value of biomarkers.
The Stephenson Cancer Center at the University of Oklahoma May 2 announced that it has received Cancer Center designation from NCI.
Recently, Peter Tunney, an artist who runs two galleries in the Wynwood Walls Park in Miami, provided artwork to wrap an RV that Sylvester Comprehensive Cancer Center will use to take cancer interventions to Little Haiti, Liberty City, Little Havana and LGBTQ neighborhoods.
Restoring the NIH budget is the singular mission of ACT for NIH, said Jed Manocherian, founder and chairman of the nonprofit advocacy organization.
Richard and Susan Rogel gave $150 million to the University of Michigan Comprehensive Cancer Center, which will now be known as the Rogel Cancer Center.
Patients and their doctors should be able to make treatment decisions without involvement from the federal government, said Starlee Coleman, senior policy advisor for the Goldwater Institute, a libertarian think tank that lobbied successfully for widespread adoption of right-to-try laws.
The right-to-try bills passed by Congress would remove FDA's expanded access mandate and leave patients at greater risk, said Arthur Caplan, the Drs. William F. and Virginia Connolly Mitty Professor and founding director of the Division of Medical Ethics at the New York University School of Medicine.
John Edward Porter, a long-time key Congressional appropriator and advocate for biomedical research, received the Research!America Legacy Award at an advocacy awards dinner March 14.
Fifteen years ago, when Ethan Basch started developing measures for aggregating patient-reported outcomes, many of his colleagues in oncology saw no promise in this enterprise.
